Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry
N/A
N/A
N/A
N/A
N/A
Open (Enrolling by invite only)
Both
Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma
Both
Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma
Trial Information
Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry
Inclusion Criteria:
- A record of medullary thyroid carcinoma (MTC) identified from state/regional
population-based cancer registries
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide and other GLP-1 analogs into the US market
Outcome Time Frame:
December 2011 to December 2025
Safety Issue:
No
Principal Investigator
Paula M. Hale
Investigator Role:
Study Director
Investigator Affiliation:
Novo Nordisk
Authority:
United States: Food and Drug Administration
Study ID:
NN2211-3965
NCT ID:
NCT01511393
Start Date:
January 2012
Completion Date:
December 2025
Related Keywords:
- Diabetes
- Diabetes Mellitus, Type 2
- Medullary Thyroid Carcinoma
- Carcinoma
- Thyroid Neoplasms
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Thyroid Diseases
Name | Location |
|---|---|
| Novo Nordisk Clinical Trial Call Center | Berlin, New Jersey 08009 |
